RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
Portfolio Pulse from
RedHill Biopharma has licensed RHB-102 to Hyloris for commercialization outside North America, potentially earning up to $60 million in milestone payments and royalties. The drug could become the first oral 24-hour extended-release ondansetron for CINV/RINV treatment.
February 25, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RedHill Biopharma has entered a licensing agreement with Hyloris for RHB-102, potentially earning up to $60 million in milestone payments and royalties. This deal excludes North America and follows positive UK MHRA advice for a UK MAA.
The licensing agreement with Hyloris provides RedHill with a significant potential revenue stream outside North America. The positive UK MHRA advice enhances the likelihood of approval, which could further boost RedHill's financial prospects.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90